Claim 70% Off TipRanks This Holiday Season
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
bioAffinity Technologies, Inc. ( (BIAF) ) has provided an announcement.
On September 18, 2023, bioAffinity Technologies’ subsidiary Precision Pathology Laboratory Services consummated the acquisition of a San Antonio-based clinical anatomic and clinical pathology laboratory business from Village Oaks Pathology Services, with related governance structured through a succession agreement restricting the transfer of equity in Village Oaks’ professional entity to ensure continuity of designated physician ownership. In December 2025, Village Oaks’ sole shareholder, 77-year-old Dr. Roby P. Joyce, informed the company of his decision to transfer 100% of his equity in Village Oaks to long-serving pathologist Dr. James Humphreys, and on December 22, 2025, Village Oaks, PPLS and Dr. Humphreys entered into a new succession agreement that similarly restricts Humphreys from disposing of his equity without consent and establishes automatic transfer mechanisms and replacement procedures to maintain a qualified designated physician and preserve Village Oaks’ business operations, contracts, licenses and other rights.
The most recent analyst rating on (BIAF) stock is a Sell with a $1.00 price target. To see the full list of analyst forecasts on bioAffinity Technologies, Inc. stock, see the BIAF Stock Forecast page.
Spark’s Take on BIAF Stock
According to Spark, TipRanks’ AI Analyst, BIAF is a Underperform.
bioAffinity Technologies, Inc. has a low overall stock score due to significant financial challenges, including declining revenues and substantial losses. Technical indicators also reflect bearish momentum, and the valuation is unattractive with a negative P/E ratio. While there are positive corporate developments, they are not enough to offset the financial and technical weaknesses.
To see Spark’s full report on BIAF stock, click here.
More about bioAffinity Technologies, Inc.
bioAffinity Technologies, Inc., through its wholly owned subsidiary Precision Pathology Laboratory Services LLC, operates in the clinical anatomic and clinical pathology laboratory industry, providing pathology and related diagnostic services, with a geographic focus that includes San Antonio, Texas.
Average Trading Volume: 2,765,233
Technical Sentiment Signal: Sell
Current Market Cap: $5.58M
For an in-depth examination of BIAF stock, go to TipRanks’ Overview page.